Remove Access Remove Clinical Trials Remove Epilepsy Remove Events
article thumbnail

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Cannabis Law Report

We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. percent, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial of 24.5 Chief Medical Officer of Marinus. “We Data Highlights.

article thumbnail

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

Cannabis Law Report

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK softens import restrictions on medicinal cannabis

Cannabis Law Report

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. It will continue to engage with medical associations and patients to build evidence, using trials in the UK to accelerate our understanding of how medicinal cannabis can benefit patients.

article thumbnail

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52
article thumbnail

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Cannabis Law Report

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Nabiximols (known as “Sativex” outside US) in the US: Commence pivotal clinical program in initial target indication of spasticity associated with Multiple Sclerosis. Work with U.S.

article thumbnail

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 646) 421-9523.